A Clinical Analysis of Parotid Tumors

Kim, Tae Seon; Noh, Dong Young; Youn, Yeo Kyu; Oh, Seung Keun; Choe, Kuk Jin

Abstract

A clinical analysis was done for 141 patients with parotid tumors who had been admitted to and treated at the Department of Surgery, Seoul National University Hospital over a period of 15 years from January 1981 to December 1995. Of these 141 cases, there were 123 cases of benign tumors and 18 cases of malignant tumors. The results were as follows ; 1) Sex distribution revealed a preponderance of females with a ratio of 1.4 : 1. When only malignant tumors were considered, males were predominant with a ratio of 1.6 : 1. 2) Benign tumors were prevalent in the 3rd & the 4th decades while malignant tumors were prevalent in the 4th & the 5th decades. 3) The chief complaint was a palpable mass in all the cases and facial nerve palsy was accompanied with 22% of malignant cases. 4) The mean size of the mass was 3.5 cm in diameter. 5) The mean duration of illness was 4.9 years with a duration of 1 year being seen in 28% of the benign tumor cases and in 44% of the malignant tumor cases. 6) The most commonly performed operative procedures were a superficial lobectomy(56%) for benign tumors and a total parotidectomy(67%) for malignant cases. And 76% of all benign tumors and 89% of all malignant tumors were treated with a superficial lobectomy or a more extensive operation. 7) According to the histopathological findings, benign tumors were present in 123 cases(87%) and malignant tumors in 18 cases(13%). The most common benign tumor was pleomorphic adenoma(80%) and the most common malignant tumor was mucoepidermoid carcinoma(50%). 8) In the 5 recurrent cases, previous operations were enucleation(4 cases) and biopsy only(1 case). 9) The postoperative complications developed in 51 cases(36%), including 33 cases(23%) of facial nerve palsy and 9 cases(6%) of Frey's syndrome. Facial palsy was permanent in 7 cases(5%). 10) Of the 94 follow-up cases, recurrences developed in 6 cases(7%) of benign tumors and 6 cases (50%) of malignant tumors.